NovaBridge to Report First Half 2026 Results and Corporate Update on August 20
核心洞察
NovaBridge Biosciences (搜索) (Nasdaq: NBP) will hold a webcast on Thursday, August 20, 2026, at 9:00 AM ET to discuss first-half 2026 financial results and recent corporate progress.
The company's pipeline is led by givastomig, a potential first-in-class Claudin 18.2 (搜索) × 4-1BB (搜索) bispecific antibody in a global Phase 2 study for gastric cancer (搜索).
VIS-101 (搜索), a dual VEGF-A (搜索) × ANG-2 (搜索) inhibitor, has completed a Phase 2a study in wet AMD with a Phase 2b study expected to begin in the second half of 2026.
NovaBridge Biosciences (搜索) (Nasdaq: NBP), a global biotechnology company advancing therapeutic programs in oncology and ophthalmology, announced it will hold a webcast on Thursday, August 20, 2026, at 9:00 AM ET (9:00 PM China Standard Time) to discuss recent corporate progress and financial results for the first half ended June 30, 2026. The live and archived webcast can be accessed through the Upcoming Events section of the Investors page on the company's website, with a replay archived for at least 30 days after the event.
The company describes itself as identifying differentiated innovation and applying disciplined development, financing, and partnering strategies to create value, with an objective to build a sustainable biotechnology company by repeatedly identifying differentiated innovation, advancing it efficiently, and bringing innovative therapies to patients.
A Pipeline Led by Givastomig in Gastric Cancer
NovaBridge's differentiated pipeline is led by givastomig, a potential first-in-class Claudin 18.2 (搜索)-Targeted Immuno Amplifier (CTIA) — a Claudin 18.2 × 4-1BB (搜索) bispecific antibody. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed, and is being developed to treat Claudin 18.2-positive gastric cancer (搜索) and other gastrointestinal malignancies.
The candidate is being evaluated in a global, randomized Phase 2 study, following positive topline results from a Phase 1b, multicenter, open-label study in first-line gastric cancer (搜索).
VIS-101 in Retinal Vascular Diseases
VIS-101 (搜索) is a purpose-designed, potential best-in-class dual VEGF-A (搜索) × ANG-2 (搜索) inhibitor. It targets VEGF-A and ANG-2 to provide more rapid, robust, and durable treatment responses for patients with retinal vascular diseases, including wet age-related macular degeneration (搜索) (wet AMD), diabetic macular edema (搜索), and retinal vein occlusion (搜索).
VIS-101 (搜索) has completed a randomized, dose-ranging Phase 2a study in wet AMD, and NovaBridge expects to initiate a dose-determining Phase 2b study in the second half of 2026. NovaBridge is the majority shareholder of Visara, Inc. (搜索), which controls global rights to VIS-101 outside of Greater China and certain countries in Asia.
Additional Programs and Partnerships
NovaBridge is collaborating with its partner, ABL Bio (搜索), on ragistomig, a bispecific antibody combining PD-L1 (搜索) as a tumor engager with 4-1BB (搜索) as a conditional T-cell activator, in solid tumors. In addition, NovaBridge holds worldwide rights outside of China to uliledlimab, an anti-CD73 (搜索) antibody targeting adenosine-driven immunosuppression in cancer.
Corporate Governance Update
Separately, the company announced it will hold its annual general meeting of shareholders (AGM) at its Shanghai office on September 8, 2026, at 10:00 a.m. Shanghai time. Holders of record of ordinary shares at the close of business on July 27, 2026, are entitled to attend and vote at the AGM, while holders of American depositary shares (ADSs) must act through the depositary, Citibank, N.A. The company has filed its annual report on Form 20-F, including audited financial statements for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission.